In analyzing over 8,300 mosaic chromosomal alterations in UK Biobank participants, Harvard researchers uncovered specific alterations that may predict for CLL.
In a large international study, pre-AML cases had greater clonal expansion and enrichment of specific gene mutations; origins of AML were detected > 5 years before it developed.
The most common presentation among the younger patients was bleeding, and they were more likely have a family history of rectal cancer.
A preclinical study of ibrutinib provides compelling evidence that myeloid leukemias with mutated G-CSFR have abnormal activation of Btk.
Strong efficacy and safety outcomes with this agent, which targets the molecular driver of an AML subset, have led to its approval in IDH1-mutated R/R disease.
In the emerging era of personalized treatment, it may be time to rethink which surrogate markers are used in AML clinical trials.
Early‐onset rectal cancer may differ biologically and in its response to multimodality therapy, according to a large retrospective study of NCCN data.
Next-generation sequencing may prove to be a useful tool in the identification of co-mutations associated with resistance, an MD Anderson study suggests.
More than 20% of patients with non–clear cell RCC had a germline mutation, and half of this group could benefit from direct systemic therapy.
An analysis by FDA and NCI investigators recommended further study of the utility of immunotherapy in patients unable to mount adequate immune responses.